Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Medical oncology > T Cell Lymphoma > Flashcards

T Cell Lymphoma Flashcards

You may prefer our related Brainscape-certified flashcards:
USMLE® Step 1 flashcards
1
Q

What is the immunophenotype of AITL?

A

CD3, CD4
+/- BCL6, CD10

May lose a subset of pan T-cell Antigens
=CD2, CD3, CD5, CD7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 2 types of Enteropathy-associated T ell lymphoma

A

Type I:

  • Typically express CD3, but do not express CD4
  • Mostly CD8-
  • Large cells within tumor infiltrate CD30+
  • TCR Beta gene is clonally rearranged.
  • Many with a HLA haplotype-associated with celiac disease
  • 50-60% have complex segmental amplification of the 9q34 region

Type II:

  • CD8+, CD56+, TCR Gamma-delta+
  • often with application of c-myc 8q24
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Most common T Cell Lymphoma?

A

PTCL, NOS

ALCL

AITL

EN NKT Cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the common cytogenetic changes typical/diagnostic of AITL?

A

Trisomy 3, 5

Additional X chromosome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the Follicular Denditrtic Cell Network?

A

CD21, CD23, CD35

Usually present in AITL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the differentials for AITL?

A

Other PTCLs
Hodgkin’s Lymphoma
EBV+ DLBCL, NOS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is AITL distinguished from other PTCLs?

A

CD10+
CXCl13+
PD-1+
FDC mesh work present (CD21, CD23, CD35)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tell me about Breast implant associated ALCL

A

Emerging entity
Described as development of ALCL around the implant (involving the fibrous capsule and/or Serena only)

Natural Hx appears generally more favorable with surgical removal to he implant alone as adequate therapy for most

Rare cases with parenchymal breast or nodal involvement may have an aggressive course more in line with systemic ALK-positive ALCL

Optimal treatment not well-defined, management should be individualized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the Newcastle regimen?

A

CHOP –> IVE (Ifosfamide, Etoposide, epirubicin), alternating with intermediate dose MTX

  • used only in patients with EATL
  • includes HSCT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the options for first line treatment of PTCL?

A

No standard treatment

Clinical trial is an option

If ALCL, ALK+,

  • CHOP-21
  • CHOEP

Other histologically:

  • CHOEP
  • CHOP-14
  • CHOP-21
  • DA-EPOCH
  • CHOP-IVE
  • HyperCVAD

1s line-consolidation

  • to consider with high-dose therapy and stem cell rescue
  • patients with low IPI ALCL, ALK+ disease in remission do not need Consolidative transplant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the possible 2nd-line treatment options for TCL that are single agents?

A

Belinostat
Brentuximab for CD30+ PTCL
Pralatrexate
Romidepsin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the available combination regimens for PTCL?

A 
DHAP (Dexa, CDDP, Cytarabine)
ESHAP(Etoposide, Methylprednisolone, Cytarabine, CDDP)
GDP (Gem, Dexa, CDDP)
GemOx (Gem, Ox)
ICE (Ifosfamide, Carboplatin, Etoposide)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Give me examples of primary nodal PTCLs

A

PTCL-NOS
ALCL - ALK+/ALK-
AITL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Give me examples of primary Extranodal PTCL

A

Enteropathy-associated TCell lymphoma (EATL)
Extranodal-natural killer/T-Cell lymphoma (ENKTCL)
Hepatosplenic T cell lymphoma (HSTCL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the general epidemiology of PTCLs?

A

Uncommon and heterogenous
Originate from post-thymic (peripheral) T cells or mature NK Cells

10-15% of all NHL
Male: Female 2:1
Median age 6th to 7th decade
Both sex & age patterns vary according to different subtypes.

Some association with certain conditions:
EBV - ENKTCL
Celiac disease - EATL
Crohn’s - HSTCL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What suggests that a given T-cell population is neoplastic?

A

1) Morphology
2) Aberrant T-Cell phenotype
3) Clonally rearranged T-Cell receptor (TCR) genes (alpha-beta vs gamma-delta)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the presumed cell of origin for:

1) PTCL-NOS
2) AITL
3) ALCL

A

1) PTCL-NOS : variable, mostly T-helper cell
2) AITL : Follicular T-helper
3) ALCL : Cytotoxic T cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What suggests a cytotoxic profile?

A

TIA1, granzyme B, perforin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the difference in immunophenotype between EATL Type I and II?

A

EATL Type I = CD8+/CD56-
EATL Type II = CD8-/CD56+

Type II is also not a/w pre-existing enteropathy

20
Q

What is the immunophenotype of ALCL?

A

CD30+, PAX5-, EMA+
1/3: CD45-

If t(2:5) present, ALK+

21
Q

What are the staging blood tests required?

A

FBC
Routine blood chemistry
LDH, Uric acid
HIV, HTLV-1, Hep B/C

22
Q

What is the management of HSTCL?

A

One of the worst prognoses. 5y OS and FFS

23
Q

What is the treatment for ENKTCL?

A

1st line - L-asparaginase containing regimens eg. SMILE and AspaMetDex
CHOP or CHOP-like tx not effective

Localized disease = Addition of RT to chemo

Stage I/II = concurrent = sequential
- RT ~>50Gy, but if radiosensitizers used, 40Gy
CNS prophylaxis not recommended
HDCT –> transplant controversial

Stage III/IV: L-asparaginase-containing regimens preferred. IF CR, then HDC with HSCT

Relapse:
Repeat biopsy
After anthracycilne-based –> L-asparagine see regimens –> gemcitabine-based –> auto/also transplant

24
Q

What are the treatment options for EATL?

A

1st line:
Outcome after standard CHOP poor
If can tolerate more aggressive chemo, IVE/MTX = Ifosfamide/vincristine/Etoposide/MTX
- this is followed by autoSCT.

CHOEP-14–>autoSCT

Relapse: no evidence. Consider allo.

25
Q

What is the treatment for nodal PTCL?

A

1) CHOEP
- those 60yo or younger. With older patients, toxicity is a limiting factor.
- consolidated by AutoSCT
2) localized Stage I disease: shortened chemo, followed by local RT
3) Brentuzimab in relapse
- ORR 86% with CR rate 60% and median response duration 12.6m
- can serve as a bridge to transplant as well

26
Q

What is the most common T Cell Lymphoma?

A

1) PTCL
2) AITL
3) NKTCL

In Asia, PTCL-NOS and NKTL are almost as equally common

27
Q

What is the average 5y OS for the TCell Lymphomas

1) Cutaneous ALCL
2) ALK+ALCL
3) Nasal NK
4) PTCL-NOS
5) ALK-ALCL
6) Extranasal NKT

A

1) Cutaneous ALCL 90%
2) ALK+ ALCL 60%
3) Nasal NKT 40%
4) PTCL-NOS 35%
5) ALK-ALCL 35%
6) Extranasal NKT 10%

28
Q

Tell me about AITL

A

1) Age: middle-aged to elderly
2) P/w: generalized LAN, HSM, prominent systemic symptoms
3) Bloods: Polyclonal Ig increase, hemolytic anemia, cold agglutinin, cryoglobulinemia
4) Morphology: polymorphic infiltrate of small-medium lymphocyte with clear cytoplasm. Arborizing high endothelial venules. Proliferation of Follicular dendritic cells
5) IHC: CD4+, loss of pan TCell Ag uncommon. CD20+, CD10+, BCL6+

29
Q

Tell me about PTCL-NOS

A

1) Age: 60yo
2) P/w: nodal involvement. Can be a combination of nodal and Extranodal involvement. Majority p/w advanced disease
3) Morphology: inter follicular, diffuse infiltrates. Medium-large cells, multilobulated forms with prominent nucleoli and focal necrosis.
4) IHC : CD2, D3, CD5, CD7,
- most single CD4+ or less often CD8+
- sometimes CD4- CD8-, rarely both positive
- >85% express TCR alpha-beta.

30
Q

What are the different patterns of AITL?

A

Pattern 1: Hyperplastic GC
Pattern 2: Regressed GC
Pattern 3: Effaced GC

Patterns 2 &3 a/w with worse survival outcome.

31
Q

What are the common molecular aberrations in AITL?

A

TET2 mutation 80%
DNMT3A mutation 30%
IDH2 mutation 20%
RHOA mutation 70%

32
Q

Tell me about ALCL

A

1) Age: ALK+ most frequent in 1st 3 decades with male predominance
- ALK+ with better prognosis
2) p/w: mostly with advanced stage and B symptoms
3) Morhpology: Large cells, horse-shoe or kidney-shaped nuclei. Donut cells tat appear to have cytoplasmic inclusions
4) IHC:
- ALK+ ALCL: EMA+ CD3-

33
Q

Describe NKTCL

A 
Asians/South Americans
53yo
Male>Female
Nasal cavity + other regions of upper aero digestive tract, skin, GI, Testis, soft tissue
Aggressive tumor with poor prognosis

Morphology : small–> Moderate –> Large cells
Angiocentric growth

IHC:

  • CD2+ ,surface CD3-, cytoplasmic CD3+, CD56+
  • CD4, CD8, TCR alpha-beta, TCR gamma-delta negative
  • TIA-1, granzyme B, Perforin usually positive
  • EBER +
34
Q

What are the first-line therapeutic options available for ALCL, ALK+?

A

CHOP-21
CHOEP-21

Low IPI ALCL, ALK+ disease in remission, do not need Consolidative therapy.

35
Q

What are the therapeutic options available for other T Cell lymphoma (excluding ALCL ALK+)

A

CHOEP
CHOP-14
CHOP-21
CHOP–> IVE (Ifosfamide, Etoposide, epirubcin) alternating with intermediate dose methotrexate
» known as the Newcastle regimen, but studied only in EATL patients
HyperCVAD alternating with HD MTX/Cytarabine
Consider consolidation with HD Therapy and stem cell rescue

36
Q

What is Denileukin diffitox?

A

Denileukin Diffitox is a fusion protein that combines fragments of diphtheria toxin with IL2.
IL2 domain targets tumor cells bearing IL2 receptor.

37
Q

What are the risks a/w Denileukin Diffitox?

A

Infusion reaction
Neutropenia
Rhabdomyolysis

38
Q

What is Denileukin Diffitox best used for?

A

AITL. ORR 80%

39
Q

What is the BENTLY trial?

A

Damaj JCO 2013

Ph II R/R TCL,

40
Q

What are the FDA approved agents for R/R PTCL?

A

Pralatrexate
Romidepsin
Belinostat
Bendamustine

41
Q

Tell me about Romidepsin

A

Coiffier JCO 2012

2 prior lines of treatment
N=130
ORR 25% with CR 15% 
Median duration of response 17m 
Med PFS 4m
42
Q

Tell me about pralatrexate

A

It is an anti-folate agent
Binds DHFR and presents dihydrofolate coversion to tetrahydrofolate.

Tetrahydrofolate is required for purine/pyrimidine and aa synthesis.

43
Q

Why does conventional chemotherapy not work well in PTCL?

A

1) Higher rate of primary refractory disease
2) Higher rate of relapse disease
3) Lack of efficacy of anthracyclines

44
Q

What is the NKT cell Lymphoma prognostic index?

A

S.L.A.B

Serum LDH > Normal
LN - N1 to N3, not M1
Ann Arbor Stage IV
B symptoms

No of risk factors
Low - 0
Low intermediate - 1
High intermediate - 2
High - 3 or 4
45
Q

What are the treatment options available for Extranodal NKT cell Lymphomas?

A

1) Combination chemotherapy
2) Concurrent CRT
3) Sequential ChemoRT
4) Sandwich ChemoRT
5) RT alone

1) Combination chemo:
- SMILE
- AspaMetDex
- GELOX

2) Concurrent ChemoRT
- DeVic protocol (RT 50Gy, Chemo3#)
- VPD

3) Sequential ChemoRT
- For stage I, II SMILE –> RT

4) Sandwich CHemoRT
- GELOX 2# –> RT –> GELOX 2-4#

5) RT alone

Medical oncology (53 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions